39 results on '"Castillo, Jessa"'
Search Results
2. Development and Initial Assessment of [18F]OP-801: a Novel Hydroxyl Dendrimer PET Tracer for Preclinical Imaging of Innate Immune Activation in the Whole Body and Brain
3. 68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG.
4. [18F]-C-SNAT4: an improved caspase-3-sensitive nanoaggregation PET tracer for imaging of tumor responses to chemo- and immunotherapies
5. Synthesis of [18F]FAraG Using a Second-Generation Precursor and Its Utility Across Multiple Radiochemistry Platforms
6. Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy
7. Abnormal [18F]FDG PET/MRI findings in paraspinal structures of patients with suspected cerebrospinal fluid leak
8. Development and initial assessment of [18F]OP-801: a novel hydroxyl dendrimer PET tracer for preclinical imaging of innate immune activation in the whole body and brain
9. Development and Initial Assessment of [18F]OP-801: a Novel Hydroxyl Dendrimer PET Tracer for Preclinical Imaging of Innate Immune Activation in the Whole Body and Brain.
10. P-041 - Synthesis of [18F]FAraG Using a Second-Generation Precursor and Its Utility Across Multiple Radiochemistry Platforms
11. Supplementary Figure from 89Zr-panitumumab Combined With 18F-FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma
12. Supplementary Table from 89Zr-panitumumab Combined With 18F-FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma
13. Supplementary Data from 89Zr-panitumumab Combined With 18F-FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma
14. Supplementary Figure S6 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
15. Supplementary Table S5 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
16. Data from In Vivo Imaging of Methionine Aminopeptidase II for Prostate Cancer Risk Stratification
17. Supplementary Movie from In Vivo Imaging of Methionine Aminopeptidase II for Prostate Cancer Risk Stratification
18. Supplementary Information from In Vivo Imaging of Methionine Aminopeptidase II for Prostate Cancer Risk Stratification
19. 89Zr-panitumumab Combined With 18F-FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma
20. A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
21. Sigma-1 Receptor Changes Observed in Chronic Pelvic Pain Patients: A Pilot PET/MRI Study
22. In Vivo Imaging of Methionine Aminopeptidase II for Prostate Cancer Risk Stratification
23. Effects of the Sigma-1 Receptor Agonist Blarcamesine in a Murine Model of Fragile X Syndrome: Neurobehavioral Phenotypes and Receptor Occupancy
24. Hippocampal subfield imaging and fractional anisotropy show parallel changes in Alzheimer's disease tau progression using simultaneous tau‐PET/MRI at 3T
25. [18F]-C-SNAT4: an improved caspase-3-sensitive nanoaggregation PET tracer for imaging of tumor responses to chemo- and immunotherapies.
26. P4-576: CONCORDANCE BETWEEN 18F-PI-2620 TAU PET/MRI IMAGING AND CLINICAL OUTCOMES IN ALZHEIMER DISEASE AND OTHER TAUOPATHIES
27. The Characterization of 18F-hGTS13 for Molecular Imaging of xC− Transporter Activity with PET
28. The characterization of 18F-hGTS13 for molecular imaging of xC- transporter activity with positron emission tomography.
29. P4‐262: SIGMA‐1 RECEPTOR TARGET OCCUPANCY STUDY WITH DYNAMIC PET SCAN ANALYSIS OF ANAVEX ® 2‐73: A CLINICAL CANDIDATE FOR NEURODEGENERATIVE AND NEURODEVELOPMENTAL DISEASES
30. P4‐315: TAU PET IMAGING WITH 18F‐PI2620 IN AGING AND ALZHEIMER'S DISEASE
31. CONCORDANCE BETWEEN 18F-PI-2620 TAU PET/MRI IMAGING AND CLINICAL OUTCOMES IN ALZHEIMER DISEASE AND OTHER TAUOPATHIES
32. TAU PET IMAGING WITH 18F-PI2620 IN AGING AND ALZHEIMER’S DISEASE
33. SIGMA-1 RECEPTOR TARGET OCCUPANCY STUDY WITH DYNAMIC PET SCAN ANALYSIS OF ANAVEX®2-73: A CLINICAL CANDIDATE FOR NEURODEGENERATIVE AND NEURODEVELOPMENTAL DISEASES
34. P4‐315: TAU PET IMAGING WITH 18F‐PI2620 IN AGING AND ALZHEIMER'S DISEASE.
35. P4‐262: SIGMA‐1 RECEPTOR TARGET OCCUPANCY STUDY WITH DYNAMIC PET SCAN ANALYSIS OF ANAVEX®2‐73: A CLINICAL CANDIDATE FOR NEURODEGENERATIVE AND NEURODEVELOPMENTAL DISEASES.
36. 68 Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18 F-FDG.
37. A Clinical PET Imaging Tracer ([ 18 F]DASA-23) to Monitor Pyruvate Kinase M2-Induced Glycolytic Reprogramming in Glioblastoma.
38. Hippocampal subfield imaging and fractional anisotropy show parallel changes in Alzheimer's disease tau progression using simultaneous tau-PET/MRI at 3T.
39. The Characterization of 18 F-hGTS13 for Molecular Imaging of x C - Transporter Activity with PET.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.